CLN7 Batten Disease · CLN7

What this is

CLN7 Batten disease is a form of neuronal ceroid lipofuscinosis (NCL), a family of inherited lysosomal storage disorders that progressively destroy the central nervous system. The condition is autosomal recessive, caused by damaging mutations in both copies of the MFSD8 gene on chromosome 4. MFSD8 encodes a lysosomal membrane protein, and its loss leaves cells unable to clear a class of waxy lipopigment that accumulates inside neurons until the neurons die.

CLN7 typically presents in late infancy or early childhood, between ages 2 and 7, with developmental regression after a period of apparently normal early development. Symptoms include loss of vision, seizures, loss of speech and motor skills, and progressive dementia. The disease is fatal. Death usually occurs in adolescence or early adulthood, with the exact age dependent on the specific mutation and the rate of progression.

The collective incidence of all NCL subtypes is roughly 1 in 100,000 live births, with regional variation. CLN7 is among the rarer NCL subtypes; published case series have reported affected children across multiple populations.

Diagnosis is by gene sequencing of MFSD8 and the broader NCL gene panel, supported by electron microscopy of skin or lymphocyte biopsy showing the characteristic curvilinear and rectilinear storage profiles inside lysosomes. There is no approved disease-modifying therapy for CLN7. Standard of care is symptomatic: anticonvulsants for seizure control, feeding support as bulbar function fails, and palliative care.

The case

Mila Makovec was a child in Colorado whose family first noticed regression around her third year of life. Her mother, Julia Vitarello, has described in foundation publications and in interviews with STAT News and other outlets a child who had developed normally and then began losing skills she had previously had. Her vision dimmed first. Her speech followed. She started stumbling, then falling. By age six Mila was having 15 to 30 seizures a day, each lasting up to two minutes, and her capacity to walk, see, and speak was failing.

Genetic testing identified one damaging variant in MFSD8. CLN7 is recessive, so a single damaging variant cannot account for the disease. The second variant was elusive. Standard exome sequencing did not find it, and without a confirmed second hit the diagnosis sat in a slot the lab could describe but not close.

In January 2017, Vitarello's outreach reached Timothy Yu, a neurologist and human geneticist at Boston Children's Hospital. Yu's team performed deeper whole-genome sequencing on Mila's DNA and identified what earlier work had missed. A transposable element, a piece of mobile DNA, had inserted itself into a non-coding region of Mila's second MFSD8 allele. The insertion introduced a cryptic splice site, so the cell was reading the gene incorrectly and producing no functional MFSD8 protein from that copy. The variant was specific to Mila. No one else in any database carried it.

Yu's team designed an antisense oligonucleotide to mask the cryptic splice site and restore correct splicing of MFSD8. Three candidate molecules corrected the splicing defect when tested in fibroblasts grown from Mila's skin biopsy. The team selected the most effective candidate, manufactured it under good manufacturing practices, ran toxicology in rats, and submitted an application to the FDA under an emergency investigational new drug pathway. The interval from identification of the second variant to first injection was approximately ten months. Standard rare-disease drug development takes a decade to fifteen years.

Mila received her first intrathecal dose of the drug, named milasen, on January 31, 2018, at Boston Children's Hospital. She was seven. Over the course of treatment her seizure frequency declined and the seizures she did have became shorter, often under one minute. Yu's team published the case in the New England Journal of Medicine in October 2019.

Milasen did not reverse the disease. By the time the drug reached her, the damage to Mila's brain had been progressing for years and was not reversible. She died on February 11, 2021, at age 10, three years after her first dose. Her mother founded Mila's Miracle Foundation, which now funds research and advocacy across the field of individualized medicine that Mila's case opened.

The research

The research enterprise that produced milasen was small and academic. Yu's lab at Boston Children's Hospital, with collaborators across the hospital and at Harvard Medical School, did the sequencing, the splice-correction analysis, the ASO design, the cell-based validation, the rodent toxicology, and the regulatory submission. The drug substance was synthesized commercially under contract; the program around it was Yu's group.

The therapeutic mechanism is splice modulation by an antisense oligonucleotide. ASOs are short synthetic strands of nucleic acid, typically 18 to 25 bases, chemically modified to resist degradation. They bind a specific RNA sequence by complementary base pairing and change how the cell processes that RNA. In Mila's case, the ASO covered the cryptic splice site introduced by the retrotransposon insertion, so the cell ignored the cryptic site and spliced MFSD8 normally. The chemistry was the same chemistry used in nusinersen, the approved ASO for spinal muscular atrophy, which served as the safety and delivery precedent for milasen's intrathecal route.

The regulatory pathway was the FDA's emergency investigational new drug mechanism, the same mechanism that had previously been used for time-critical compassionate use of investigational therapies. There was no individualized-therapy framework at the time. Each step of milasen's development, the toxicology design, the manufacturing scale, the dosing regimen, was negotiated with the FDA case by case.

Funding came from Vitarello's organizing through Mila's Miracle Foundation and from research dollars Yu's group had already secured. Reporting in STAT News and elsewhere has placed the development cost of milasen at roughly $2 million, almost all of it spent on GMP manufacturing, toxicology, and regulatory preparation rather than on the molecule itself. The cost of synthesizing a single ASO at research scale is in the thousands of dollars; the cost of manufacturing one to clinical-grade specifications, with the surrounding toxicology and quality work, is what dominates the total.

Kim and colleagues published the case as "Patient-customized oligonucleotide therapy for a rare genetic disease" in the New England Journal of Medicine in 2019 (PMID 31597037). The paper described the variant, the ASO design, the cell-based and animal-toxicology data, the regulatory pathway, and the clinical course. It became the canonical reference for n-of-1 ASO development.

What is blocking the next case

Manufacturing capacity is the first barrier. The number of contract development and manufacturing organizations that will produce a clinical-grade ASO at one-person scale, on a timeline measured in months, is small. The minimum order quantity for a GMP run is calibrated to commercial drug development and does not scale down efficiently to one person. Each n-of-1 ASO program either commissions a custom run or finds capacity at one of the few academic or non-profit GMP facilities working in the space. Cost is the symptom; the underlying constraint is industrial capacity.

Regulatory predictability is the second. The FDA has issued draft guidance on individualized antisense oligonucleotide drug products and has reviewed individual cases through expanded-access mechanisms, but there is no general approval pathway for a one-person therapy. Each case is negotiated in the same emergency IND framework Yu's team used. The negotiation duplicates work across cases, and the absence of a formal pathway leaves families dependent on which institution and which FDA division they are routed to.

Funding is the third. Mila's Miracle Foundation, the SLC6A1 Connect organization, the Pirovolakis family's effort for SPG50, and the other family-led programs each raised millions of dollars privately, mostly from personal networks and small grants. There is no insurance coverage for a one-person drug. Reimbursement infrastructure is built around therapies that are approved and priced for populations.

Data infrastructure is the fourth. Each ultra-rare program rebuilds the natural history of the underlying condition before treatment, because no shared registry exists for most of these conditions. Each program builds its own outcome measures, because no validated endpoint scaled to a single individual has been established. The work of milasen's development is in the published paper, but the working files, the assay protocols, the sequencing pipelines, and the regulatory correspondence remain inside individual labs. The next case starts close to scratch.

Where this connects

The milasen case is the first data point in a pattern. The pattern is described in The N-of-1 Trial as Infrastructure: the proof that a drug can be designed and delivered for one person on a timeline of months is now several years old, and the limiting factor has shifted from whether it can be done to whether the manufacturing, regulatory, and data layers around it can be made repeatable. Mila's case made the question askable. The next ten cases test whether the answer scales.

Sources

• Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019;381(17):1644-1652. PMID: 31597037.
• Mole SE, Williams RE, Goebel HH. The Neuronal Ceroid Lipofuscinoses (Batten Disease). 2nd ed. Oxford University Press; 2011. Reference text on NCL genetics, clinical course, and pathology, including CLN7/MFSD8.
• Online Mendelian Inheritance in Man (OMIM). Ceroid Lipofuscinosis, Neuronal, 7; CLN7. Entry #610951. Reference summary of the MFSD8 gene and CLN7 phenotype.
• Mila's Miracle Foundation. https://milasmiracle.org. Source for biographical details about Mila Makovec, her family's organizing, and the founding of the foundation.
• Begley S. By treating just one girl, scientists took a leap toward a new kind of medicine. STAT News. October 9, 2019. Independent reporting on the NEJM publication, the development timeline, and the approximate $2 million cost estimate.
• US Food and Drug Administration. Investigational new drug applications for individualized antisense oligonucleotide drug products to treat severely debilitating or life-threatening diseases: draft guidance for sponsor-investigators. (FDA guidance documents related to the IND pathway used for milasen and subsequent n-of-1 ASOs.)